Examples of preclinical studies and clinical trials on vaccines developed for infectious diseases

CHIKVMV-CHIKVProtection against CHIKV challenges in macaques [63]
MV-CHIKVSeroconversion in 100% of volunteers in phase I [64]
MV-CHIKVGood safety, and strong immune responses in phase II [65]
EVDVSV-EBOV-GPProtection against two EBOV strains in macaques [66, 67]
VSV-EBOV-GPGood safety and tolerability in phase I volunteers [68]
VSV-ZEBOVHigh vaccine efficacy, and protection in phase III [69]
VSV-ZEBOVHigh vaccine efficacy in phase III volunteers [70]
VSV-ZEBOVApproval of ERVEBO® by the FDA and EMA [71]
ZIKVMV-ZIKV-EZIKV-specific Abs, protection against ZIKV of mice fetus [72]
MV-ZIKV-EDespite the completion of phase I, no results are available [73]
MV-ZIKV-RSP-EPhase I study in progress [75]
MV (TMV-083)Th1-biased Ab and T cell responses in mice [76]
MV (TMV-083)Weak immune responses, phase I trial discontinued [77, 78]
COVID-19VSV-SARS-CoV-2 SProtection against SARS-CoV-2 challenges in mice [79]
VSV (V590)Weak immune responses, phase I trial discontinued [80, 81]
VSVΔG-SARS-CoV-2 SProtection against SARS-CoV-2 in hamsters [82]
VSVΔG-SARS-CoV-2 SPhase I/II study in progress [83]
LNP-nCoVsaRNAStrong SARS-CoV-2 specific Ab responses in mice [86]
LNP-nCoVsaRNASafe but not 100% seroconversion in phase I [87]

Ab: antibody; CHIKV: chikungunya virus; EBOV-GP: Ebola virus-glycoprotein; EMA: European Medicines Agency; EVD: Ebola virus disease; FDA: US Food and Drug Administration; LNP: lipid nanoparticle; LNP-nCoVsaRNA: LNP-VEE-SARS-CoV-2 S RNA; SARS-CoV-2 S: SARS-CoV-2 spike; ZEBOV: EBOV-Zaire strain